anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington&#39;s disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
PURPOSE:To obtain a preventive or therapeutic agent for fatty liver, containing a diglyceride as an active ingredient and having action on prevention of a rise in lipid concentration in the liver and high safety. CONSTITUTION:A preventive or therapeutic agent for fatty liver containing a diglyceride, e.g. a compound expressed by the formula (two of R&lt;1&gt; to R&lt;3&gt; are acyl derived from a 12-22C saturated fatty acid or unsaturated fatty acid and the rest is H), preferably a compound having an acyl group derived from a 16-20C unsaturated fatty acid as an active ingredient. The aforementioned diglyceride is obtained by transesterification of, e.g. a mixture of fats and oils (e.g. rapeseed oil) with glycerol in the presence of an alkali (earth) metallic hydroxide or reacting a lipase with a mixture of a fatty acid or its ester with the glycerol and conducting esterifying reaction.
Systems and methods for prescription medication selection, ordering, and payment are disclosed. Medication information may be received via a first computing device located at a healthcare provider premises. The medication information for a patient&#39;s medication may then be sent to a plurality of medication providers. One or more offers to fulfill the medication may be received from the plurality of medication providers. The one or more offers may then be sent to a second computing device located at the healthcare provider premises. A selection of an offer may be received from the second computing device. The selection of the offer may be indicated to the medication provider associated with the selected offer.
In one aspect, a computerized method for generating a personalized digital software application comprising: providing an application modeler engine. With the application modeler engine the method provides a graphical display of a palate that comprises a list all the nodes that are available to include in an application definition file(s). The application modeler engine receives a set of nodes via a drag and drop operation into the application definition file. The application modeler engine defines and integrates a chatbot into the personalized digital software application. The application modeler engine automatically creates the application definition file to run on a mobile device of the patient, wherein the application definition file follows a protocol and logic created in the application by a care team and the drag and dropped nodes. The application modeler engine uses the application definition file to generate the application from the application definition file. The application modeler engine deploys the application to a user&#39;s mobile device.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for preparing active oxygen species which can be generated efficiently and easily, a method for purifying a matter to be purified efficiently and easily, and a therapeutic agent for cancer useful for treating non-invasive cancer.  &lt;P&gt;SOLUTION: The active oxygen species is prepared by irradiating a coiled carbon fiber with ultrasonic waves while the coiled carbon fiber is dispersed or placed in a generated liquid containing water. The method for purifying the matter to be purified applies the method for preparing the active oxygen species. The matter to be purified is purified by irradiating the coiled carbon fiber with ultrasonic waves while the coiled carbon fiber is dispersed or placed in a purification liquid containing water and the matter to be purified. The therapeutic agent for cancer contains the coiled carbon fiber as an active ingredient, is constituted to be administered in a human body and to generate the active oxygen species in a human body by the irradiation with ultrasonic waves, and is prepared by applying the method for preparing the active oxygen species.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Pharmaceutical compositions which possess anticonvulsant properties comprise one or more amine derivatives of the formula &lt;FORM:1028234/A5-A6/1&gt; wherein X is -CH2 . CHR- or CH=CH-, R is hydrogen or alkyl, R1 is hydrogen or alkyl, R2 is hydrogen or alkyl or alkenyl optionally substituted by a hydroxy radical, or wherein R1 and R2 are joined to form together with the adjacent nitrogen atom a heterocyclic ring and wherein ring A and/or ring B may optionally be further substituted by one or more radicals selected from halogen atoms, alkoxy, alkyl and haloalkyl radicals, or a salt thereof, and a diluent or carrier therefor.  The heterocyclic ring may be pyrrolidine, piperidine or morpholine.  The compositions may be in the form of tablets, capsules, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions, or dispersible powders, and they may be formulated with conventional excipients.  The tablets may be coated in order to provide sustained release of the active ingredients.  The compositions may also contain phenobarbitone, 5,5-diphenylhydantoin or primidone.
The present invention relates to a method of automatically classifying sleep stages through an existing deep neural network. A deep neural network, trained in advance by a user measuring electroencephalogram, automatically predicts a sleep stage. It is very time consuming for sleep experts to manually classify sleep stages, and to manually classify sleep stages is also expensive because all the various biological signals must be extracted. In addition, because the subjective judgment of sleep experts is the mainstay, accurate and stable sleep stage classification is not possible. The present invention relates to an automatic sleep stage classification system using electroencephalogram, comprising the steps of: measuring an electroencephalogram corresponding to a user&#39;s sleep state; performing frequency high-pass filtering to remove noise from the measured electroencephalogram; allowing classification of sleep stages by dividing the pre-processed electroencephalogram signal into 30-second increments; classifying, by a deep neural network, sleep stages for data divided into 30-second increments; and sending classified sleep stages to the user&#39;s computer monitor or smartphone. This method is much faster, more stable, more accurate, and cost-saving compared to the manual sleep stage classification of sleep experts.
PURPOSE: To provide the subject new compound produced by culturing a valinoctin-producing microorganism belonging to the genus Streptomyces, effective for inhibiting farnesyl protein transferase and suppressing the proliferation of human cancer cell, having low toxicity and useful e.g. for a carcinostatic agent. CONSTITUTION: This new compound is valinoctin A or valinoctin B expressed by formula I (R is H for valinoctin A and methyl for valinoctin B), its acid addition salt or a compound of formula II (R&lt;1&gt; is an alkyl) consisting of an alkyl ester of the compound of formula I. The compound is effective for inhibiting farnesyl protein transferase and suppressing the proliferation of human cancer cell. The valinoctin A and/or valinoctin B can be separated from the cultured product of a microorganism belonging to the genus Streptomyces and capable of producing valinoctin A and valinoctin B [e.g. Streptomyces sp. MJ858-NF3 (FERM P-14082)].
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a scrubbing agent having an excellent feeling of use without imparting an unpleasant skin irritation feeling, a feeling of foreign materials, etc., during use and having excellent scrubbing effects and to provide a skin detergent composition comprising the scrubbing agent.  &lt;P&gt;SOLUTION: The scrubbing agent is characterized by comprising carnauba wax. The preferable average particle diameter of the scrubbing agent is 50-1,000 μm. The skin detergent composition is characterized by comprising the scrubbing agent. The preferable content of the scrubbing agent is 0.1-20 wt.%.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
The methods shall be applied in dentistry, restorative procedures and research. It performs an intraoral scan of the patient&#39;s teeth at intervals in time. Computed tomography (CBCT) of the patient&#39;s mouth is also performed and a patient file is created from the images from each scan. They are saved and used for subsequent restoration of dental status. The first scanning (3, 3n) for the patient (2, 2n) file (4, 4n) by intraoral scanner is at the occlusion of the first permanent teeth, and the computed tomography (CBCT) imaging (6, 6n) is determined individually. This creates the maxillofacial oral status of each patient by adding to his file a photo image (7, 7n) of the face , as all files (4, 4n) are saved in a database for the oral and maxillofacial status (5). From the images from the intraoral scanner, CBCT and the photo image are made combined images (8, 8n) as well as intermediate images, representing overlapping of selected images by at least one of the means used - the intraoral scanner, CBCT and camera. By means of the images the maxillofacial status database (5) is updated and supported. The database (5), besides (A) restoration of dental status, can be used for at least one of following: (B) diagnosis of other diseases, (C) making dental veneers, (D) creating dental forms marketing (E) identification of natural persons (E) research. According to the created method for making dental veneers using the database for the maxillofacial status, whereby a 3D image of the patient&#39;s teeth is downloaded from the database in its entirety, after which the dentin and tooth enamel parts of each tooth are printed separately on a 3D printer (10), thus obtaining two components, which are glued with a composite mediator, and then is made an occlusal splint for the teeth in the dentition and an occlusal register is printed out.
Lipid nanoparticles (LNPs) have emerged as a promising delivery vehicle for realizing the therapeutic potential of RNA. Developing effective extrahepatic-targeting LNP formulations has been elusive, however, particularly when targeting the central nervous system (CNS). This work demonstrates the ability of AiLNP, METiS&#39; proprietary AI-driven organ-targeted LNP discovery engine, to rapidly (&lt;2 months) create proprietary LNPs specifically optimized for CNS delivery. AiLNP-designed LNPs loaded with siRNA achieved &gt;80%knockdown of HTT mRNA in the whole brain of adult mice after a single intrathecal dose of 0.75 mg/kg siRNA, while naked siRNA was unable to achieve knockdown at any dose. Tissue microscopy found that the optimized LNPs uniformly delivered siRNA to deep brain regions in the cortex, hippocampus, and cerebellum. The LNPs showed clear signs of safety, with no hematologic toxicity, systemic bleeding, or body weight changes. Beyond siRNA, AiLNP has also been applied to optimize LNPs for CNS delivery of mRNA and ASOs. These results highlight the potential of AiLNP to significantly improve the design of LNPs that can successfully deliver payloads to the CNS.
The present invention provides a bcl-2 gene inhibitory element (BIE), which can inhibit expression of a gene in position-dependent and orientation-dependent manner. The invention provides, for example, BIE-1, having the nucleotide sequence 5&#39;-CAAGAATGCAA-3&#39; (SEQ ID NO: 1), which acts in an orientation-dependent and position-dependent manner to down-regulate the expression of the bcl-2 gene. The invention also provides a BIE binding factor (BBF), which is a cellular factor that can bind to a BIE. The invention provides, for example, BBF-A, which binds to BIE-1, including a nucleic acid sequence (SEQ ID NO: 8) encoding a portion of the amino acid sequence (SEQ ID NO: 9) of BBF-A. The invention further provides an antibody that specifically binds BBF-A. The invention also provides screening assays for identifying agents that can increase or decrease the binding of a BBF to a BIE, modulate the expression of a nucleic acid molecule linked to a BIE or modulate apoptosis in a cell.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a preparation which does not develop transient irritation while having microbial contamination resistance even without using a general- purpose preservative such as parabens.  &lt;P&gt;SOLUTION: This cosmetic for hypersensitive skin is obtained by adding (1) 1,2-hexylene glycol and (2) an antimicrobial phospholipid to cosmetic. Linoleamidopropyl PG-dimonium chloride phosphate, cocoamidopropyl PG- dimonium chloride phosphate and sodium coco PG-dimonium chloride phosphate, or the like, are preferably exemplified as the antimicrobial phospholipid. The cosmetic as a preferable form does not contain the conventional preservative such as methylparaben. A polyhydric alcohol except the 1,2-hexylene glycol may be cited as a preferable arbitrary component.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A system for wirelessly monitoring the health of an infant comprising a sensing module removably disposed within a wearable article. At least a portion of the sensing module can be in contact with an infant&#39;s foot. The sensing module can include a processing unit configured to receive and process health readings received by the sensing module. A wireless transmitter can also be in communication with the processing unit. The wireless transmitter can be configured to transmit the processed health readings to a receiving station. The receiving station can indicate an alarm if the processed health readings indicate a health trend that falls outside of a particular threshold.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a cancer stem cell, to provide the cancer stem cell produced by the method, to provide a method for screening a cancer stem cell-targeting substance and a method for screening an anticancerous substance using the cancer stem cell, to provide a pharmaceutical composition comprising the substances obtained by the methods and to provide a diagnostic method for cancer including a step of detecting a protein or an mRNA which is specifically expressed in the cancer stem cell.  &lt;P&gt;SOLUTION: The method for producing the cancer stem cell includes a step of feeding a normal cell to Ras activation and p53 deficiency. The cancer stem cell is produced by the method. Furthermore, the method for screening the cancer stem cell-targeting substance and the method for screening the anticancerous substance using the cancer stem cell are provided. The pharmaceutical composition comprises the substances obtained by the methods. The diagnostic method for the cancer includes the step of detecting the protein or the mRNA which is specifically expressed in the cancer stem cell.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A composition for X-ray visualization of body organs &amp;c contains at least 50 per cent of a sodium lead chelate of a synthetic polyamino polycarboxylic acid, e.g. ethylene- or propylene-diamine tetracetic acid, trimethylenediamine tetracetic acid, 1,2-diaminocyclohexane tetracetic acid, mono(hydroxyethyl)ethylene diamine triacetic acid, monobenzylethylene diamine triacetic acid.  Disodium lead ethylene diamine tetracetic acid is prepared by adding a small molar excess lead carbonate to an aqueous slurry of the acid and then adjusting the pH to 7.3 by sodium hydroxide solution, the excess lead precipitating being removed by filtration.ALSO:A composition for X-ray visualization of body organs &amp;c., contains at least 50 per cent of a sodium lead chelate of a synthetic polyamino polycarboxylic acid, e.g. ethylene- or propylene - diamino tetraacetic acid, trimethylenediamine tetraacetic acid, 1,2-diamino-cyclohexane tetraacetic acid, mono-(hydroxyethyl)ethylene diamine triacetic acid. The sodium calcium chelates of these acids may also be present in the proportion of 1 : 1-20 of the sodium lead chelate.  Aqueous solutions of pH 7.3-7.5 containing up to 15 per cent lead are suitably employed.  The preparation of disodium lead ethylenediamine tetraacetic acid is described (see Group IV (b)).
FIELD: medicine. SUBSTANCE: wound- healing product is based upon well-available plant raw material and bee keeping products. The present ointment contains bee wax, honey, powder of plantain leaves, castor oil and butter taken at certain quantitative ratio. The ointment in question is of anesthetic, antiphlogistic, bactericidal and resolving actions. It affects wound surface, favors quicker restoration of affected tissue, considerably improves patient&#39;s state in more shortened terms and reveals high tolerance and no side effects. EFFECT: higher efficiency.
The technology develops a new time perception and food ingredient based recommendation model method, and the model simultaneously considers the aspects of diet health advice, food ingredients, time factors, data sparsity, food clusters and controllability. The method specifically considers health factor and component content of food. In short, it will recommend the desired health food to the active user. To predict user-based scores, we first consider the user&#39;s historical scores. We use a novel attribute community detection algorithm to divide the initial food into groups and predict the rating of unrated food accordingly. Based on both types of rating predictions, i.e. based on the user and based on the food ingredients, the method predicts the final rating of the unrated food product. The first N health foods are finally recommended by considering a novel controllable multi-objective function that can clearly elucidate the health characteristics of the foods.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a foreign matter free and high-quality liposome with a narrow diameter distribution of the size of several tens to 150 nm.  &lt;P&gt;SOLUTION: A liposome manufacturing device is operated by irradiation with a low-frequency ultrasonic and a high-frequency ultrasonic while circulating a liposome raw liquid. An ultrasonic irradiation means comprises a low-frequency ultrasonic irradiation means and a high-frequency ultrasonic irradiation means. The liposome manufacturing method is characterized by preparing a fine liposome by irradiating the raw liquid with a plurality of and different frequency ultrasonic. The high-quality liposome less in degeneration effect by cavitation can be high efficiently manufactured by the invention.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To provide an activator for DELTA5- or DELTA6-unsaturating enzyme containing, as active ingredient, at least one kind selected from papaverine derivatives, piperazine derivatives and amylolide. CONSTITUTION:The objective activator containing, as active ingredient, at least one kind selected from papaverine derivatives (e.g. verapamil), piperazine derivatives (e.g. flunarizine) and amylolide. Combination of this activator with a lipid (e.g. linoleic acid) can enhance this activator&#39;s effect as functional factor. The activator can be administered orally or parenterally, its dose being 1-100mg/ day or 0.1-5mg/day for oral or parenteral administration, respectively. Activation of the DELTA5- or DELTA6-unsaturating enzyme can raise the highly unsaturated fatty acid content of the living body and can also raise the level of eicosanoid transformed therefrom.
A method for monitoring an individual&#39;s drug regimen and meal regimen to reduce the likelihood of a drug-to-food interaction. An ingredient group table is constructed that includes ingredient groups which are known to cause an adverse reaction when combined with a particular drug in an individual. Known drugs are linked to contraindicated ingredient groups listed in the ingredient group table to create a drug-ingredient group table, which includes the known drugs and the linked contraindicated ingredient groups. The drug regimen of an individual is determined from a Physicians&#39; Orders database. The drug-ingredient group table is searched using the individual&#39;s drug regimen as the search criteria. Matching drugs along with the linked contraindicated ingredient groups are extracted from the drug-ingredient group table and placed in a personalized drug-ingredient group table. A personalized contraindicated ingredient group table is created by extracting the contraindicated ingredient groups of the personalized drug-ingredient group table. Food items from an institutions menu are linked to the ingredient groups of the ingredient group table to create a food-ingredient group table, which includes the food items and the linked ingredient groups. The meal regimen of an individual is determined from dietary software or other means. The food-ingredient group table is searched using the individual&#39;s meal regimen as the search criteria. Matching food items along with the linked ingredient groups are extracted from the food-ingredient group table and placed in a personalized food-ingredient group table. The ingredient groups linked to each food item of the personalized food-ingredient group table are compared to the personalized contraindicated ingredient group table. If there are one or more matching ingredient groups between the two tables, a contraindication warning is issued. If there are no matching ingredient groups, then the meal may be served to the individual.
The present invention discloses a preparation method of a gynaecologic capsule for regulating menstruation. The present invention is characterized in that four kinds of traditional Chinese medicines, such as white atractylodes rhizome, etc. are pulverized; six kinds of traditional Chinese medicines, such as cyperus tuber, etc. are added with water to be decocted; the decocted liquid is concentrated into thick paste; the fine powder and auxiliary materials are added to be granulated, dried and encapsulated, or the decocted liquid is concentrated and dried to be prepared into dry paste powder which is encapsulated after being uniformly mixed with the fine powder and the auxiliary materials, and the whole preparation process is finished. Compared with the original preparation type, the medicine has the advantages of reasonable technology, and simple and convenient production; the affective ingredients of the medicine can be better reserved; the therapeutic effect is enhanced; quality control standards are roundly enhanced. The present invention has important significance for enhancing product quality, and is capable of better satisfying and ensuring people&#39;s medication requirements. The medicine has the functions of nourishing blood, regulating menstruation and alleviating pain, and is used for treating symptoms of menoxenia, bellyache in menstrual periods, etc. The medicine is convenient to carry and use, is a safe, stable and effective medicine and is an ideal product of modern pharmaceutical enterprises.